An adaptive randomised placebo controlled phase II trial of antivirals for COVID-19 infection (VIRCO): A structured summary of a study protocol for a randomised controlled trial

Objectives Primary objective: To determine the efficacy of a candidate antiviral on time to virological cure compared to standard of care within 14 days of randomisation Secondary objectives: • To determine the safety of the antiviral • To determine the clinical benefit of the antiviral over placebo...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Current controlled trials in cardiovascular medicine Jg. 21; H. 1; S. 847 - 3
Hauptverfasser:	McMahon, James H., Lau, Jillian S. Y., Roney, Janine, Rogers, Benjamin A., Trubiano, Jason, Sasadeusz, Joseph, Molton, James S., Gardiner, Bradley, Lee, Sue J., Hoy, Jennifer F., Cheng, Allen, Peleg, Anton Y.
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	London BioMed Central 13.10.2020 BioMed Central Ltd Springer Nature B.V BMC
Schlagworte:	Amides - adverse effects Amides - therapeutic use Antiviral agents Antiviral Agents - adverse effects Antiviral Agents - therapeutic use Australia - epidemiology Betacoronavirus - drug effects Betacoronavirus - genetics Biomarkers - metabolism Biomedicine Clinical Protocols community Coronavirus Infections - drug therapy Coronavirus Infections - epidemiology Coronavirus Infections - virology Coronaviruses COVID-19 COVID-19 study protocols Drug therapy favipiravir Female Health Sciences Hospitalization - statistics & numerical data Humans Letter Male Medicine Medicine & Public Health Pandemics Placebos Placebos - administration & dosage Pneumonia, Viral - drug therapy Pneumonia, Viral - epidemiology Pneumonia, Viral - virology protocol Pyrazines - adverse effects Pyrazines - therapeutic use Randomised controlled trial Safety SARS-CoV-2 Severe acute respiratory syndrome coronavirus 2 Statistics for Life Sciences Testing treatment Treatment Outcome Australia COVID-19 treatment adaptive protocol Randomised controlled trial community favipiravir
ISSN:	1745-6215, 1745-6215
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!